Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

Bram De Laere^#^{1

2}, Alessio Crippa^#¹, Andrea Discacciati¹, Berit Larsson¹, Maria Persson¹, Susanne Johansson¹, Sanne D'hondt³, Rebecka Bergström¹, Venkatesh Chellappa¹, Markus Mayrhofer⁴, Mahsan Banijamali¹, Anastasijia Kotsalaynen¹, Céline Schelstraete⁵, Jan Pieter Vanwelkenhuyzen^{1

2}, Marie Hjälm-Eriksson⁶, Linn Pettersson⁷, Anders Ullén⁸, Nicolaas Lumen⁵, Gunilla Enblad⁹, Camilla Thellenberg Karlsson¹⁰, Elin Jänes¹¹, Johan Sandzén¹², Peter Schatteman¹³, Maria Nyre Vigmostad¹⁴, Martha Olsson¹⁵, Christophe Ghysel¹⁶, Brieuc Sautois¹⁷, Wendy De Roock¹⁸, Siska Van Bruwaene¹⁹, Mats Anden²⁰, Ingrida Verbiene²¹, Daan De Maeseneer²², Els Everaert²³, Jochen Darras²⁴, Bjørg Y Aksnessether²⁵, Daisy Luyten²⁶, Michiel Strijbos²⁷, Ashkan Mortezavi^{28

29}, Jan Oldenburg³⁰, Piet Ost^{2

31}, Martin Eklund^#¹, Henrik Grönberg^#^{32

33}, Johan Lindberg^#³⁴

Affiliations

¹ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
² Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
³ Health, Innovation and Research Institute (Clinical Trial Unit), University Hospital Ghent, Ghent, Belgium.
⁴ National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
⁵ Department of Urology, University Hospital Ghent, Ghent, Belgium.
⁶ Department of Oncology, Capio Saint Göran's Hospital, Stockholm, Sweden.
⁷ Department of Oncology, Länssjukhuset Ryhov, Jönköping, Sweden.
⁸ Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.
⁹ Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
¹⁰ Department of Oncology, University Hospital of Umeå, Umeå, Sweden.
¹¹ Department of Oncology, Sundsvalls sjukhus, Sundsvall, Sweden.
¹² Department of Oncology, Centralsjukhuset Karlstad, Karlstad, Sweden.
¹³ Department of Urology, Onze Lieve Vrouwziekenhuis, Aalst, Belgium.
¹⁴ Department of Oncology, Stavanger University Hospital, Stavanger, Norway.
¹⁵ Department of Oncology, Centrallasarettet Växjö, Växjö, Sweden.
¹⁶ Department of Urology, AZ Sint Jan Brugge AV, Bruges, Belgium.
¹⁷ Department of Oncology, CHU de Liège - site Sart Tilman, Liège, Belgium.
¹⁸ Department of Oncology, Ziekenhuis Oost- Limburg, Genk, Belgium.
¹⁹ Department of Urology, AZ Groeninge, Kortrijk, Belgium.
²⁰ Department of Oncology, Länssjukhuset i Kalmar, Kalmar, Sweden.
²¹ Department of Oncology, Falu lasarett, Falu, Sweden.
²² Department of Oncology, AZ Sint-Lucas, Bruges, Belgium.
²³ Department of Oncology, Vitaz campus Sint-Niklaas Lodewijk, Sint-Niklaas, Belgium.
²⁴ Department of Urology, AZ Damiaan, Oostende, Belgium.
²⁵ Department of Oncology, Ålesund Hospital, Ålesund, Norway.
²⁶ Department of Oncology, Virga Jessa, Hasselt, Belgium.
²⁷ Department of Oncology, GZA Sint-Augustinus, Antwerpen, Belgium.
²⁸ Department of Urology, Universitätsspital Basel, Basel, Switzerland.
²⁹ Department of Urology, Universitätsspital Zürich, Zürich, Switzerland.
³⁰ Department of Oncology, Akershus University Hospital, Nordbyhagen, Norway.
³¹ Department of Radiation Oncology, GZA Sint-Augustinus, Antwerpen, Belgium.
³² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. henrik.gronberg@ki.se.
³³ Prostatacancer Centrum, Capio S:t Görans Sjukhus, Stockholm, Sweden. henrik.gronberg@ki.se.
³⁴ Department of Medical Epidemiology and Biostatistics, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.

^# Contributed equally.

PMID: 39198712
PMCID: PMC11564099
DOI: 10.1038/s41591-024-03268-0

Published Erratum

Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

Bram De Laere et al. Nat Med. 2024 Nov.

. 2024 Nov;30(11):3381.

doi: 10.1038/s41591-024-03268-0.

Authors

Affiliations

¹ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
² Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
³ Health, Innovation and Research Institute (Clinical Trial Unit), University Hospital Ghent, Ghent, Belgium.
⁴ National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.
⁵ Department of Urology, University Hospital Ghent, Ghent, Belgium.
⁶ Department of Oncology, Capio Saint Göran's Hospital, Stockholm, Sweden.
⁷ Department of Oncology, Länssjukhuset Ryhov, Jönköping, Sweden.
⁸ Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.
⁹ Department of Oncology, Uppsala University Hospital, Uppsala, Sweden.
¹⁰ Department of Oncology, University Hospital of Umeå, Umeå, Sweden.
¹¹ Department of Oncology, Sundsvalls sjukhus, Sundsvall, Sweden.
¹² Department of Oncology, Centralsjukhuset Karlstad, Karlstad, Sweden.
¹³ Department of Urology, Onze Lieve Vrouwziekenhuis, Aalst, Belgium.
¹⁴ Department of Oncology, Stavanger University Hospital, Stavanger, Norway.
¹⁵ Department of Oncology, Centrallasarettet Växjö, Växjö, Sweden.
¹⁶ Department of Urology, AZ Sint Jan Brugge AV, Bruges, Belgium.
¹⁷ Department of Oncology, CHU de Liège - site Sart Tilman, Liège, Belgium.
¹⁸ Department of Oncology, Ziekenhuis Oost- Limburg, Genk, Belgium.
¹⁹ Department of Urology, AZ Groeninge, Kortrijk, Belgium.
²⁰ Department of Oncology, Länssjukhuset i Kalmar, Kalmar, Sweden.
²¹ Department of Oncology, Falu lasarett, Falu, Sweden.
²² Department of Oncology, AZ Sint-Lucas, Bruges, Belgium.
²³ Department of Oncology, Vitaz campus Sint-Niklaas Lodewijk, Sint-Niklaas, Belgium.
²⁴ Department of Urology, AZ Damiaan, Oostende, Belgium.
²⁵ Department of Oncology, Ålesund Hospital, Ålesund, Norway.
²⁶ Department of Oncology, Virga Jessa, Hasselt, Belgium.
²⁷ Department of Oncology, GZA Sint-Augustinus, Antwerpen, Belgium.
²⁸ Department of Urology, Universitätsspital Basel, Basel, Switzerland.
²⁹ Department of Urology, Universitätsspital Zürich, Zürich, Switzerland.
³⁰ Department of Oncology, Akershus University Hospital, Nordbyhagen, Norway.
³¹ Department of Radiation Oncology, GZA Sint-Augustinus, Antwerpen, Belgium.
³² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. henrik.gronberg@ki.se.
³³ Prostatacancer Centrum, Capio S:t Görans Sjukhus, Stockholm, Sweden. henrik.gronberg@ki.se.
³⁴ Department of Medical Epidemiology and Biostatistics, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.

^# Contributed equally.

PMID: 39198712
PMCID: PMC11564099
DOI: 10.1038/s41591-024-03268-0

No abstract available

PubMed Disclaimer

Erratum for

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.
De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, D'hondt S, Bergström R, Chellappa V, Mayrhofer M, Banijamali M, Kotsalaynen A, Schelstraete C, Vanwelkenhuyzen JP, Hjälm-Eriksson M, Pettersson L, Ullén A, Lumen N, Enblad G, Thellenberg Karlsson C, Jänes E, Sandzén J, Schatteman P, Nyre Vigmostad M, Olsson M, Ghysel C, Sautois B, De Roock W, Van Bruwaene S, Anden M, Verbiene I, De Maeseneer D, Everaert E, Darras J, Aksnessether BY, Luyten D, Strijbos M, Mortezavi A, Oldenburg J, Ost P, Eklund M, Grönberg H, Lindberg J. De Laere B, et al. Nat Med. 2024 Nov;30(11):3291-3302. doi: 10.1038/s41591-024-03204-2. Epub 2024 Aug 20. Nat Med. 2024. PMID: 39164518 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

Affiliations

Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources